December 2023 in “Journal of dermatology” Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
September 2022 in “Plastic and Reconstructive Surgery” Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
September 2025 in “Frontiers in Immunology” Atopic dermatitis and alopecia areata share immune and genetic factors, and targeted therapies may help both.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
May 2025 in “RCMOS - Revista Científica Multidisciplinar O Saber” Combining different therapies is needed for effective male hair loss treatment.
October 2024 in “Scientific Reports” OXTR agonists may promote hair growth and be effective for treating hair loss.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
4 citations
,
November 2025 in “Nature Reviews Disease Primers” 4 citations
,
July 2024 in “The Journal of Dermatology” Alopecia areata in Dubai mostly affects men, often involves autoimmune disorders, and has high healthcare costs, especially for psychological issues.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.